niacinamide has been researched along with Thrombosis in 22 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The survival benefit of combining sorafenib and transarterial chemoembolization (TACE) therapy compared with sorafenib monotherapy for patients with advanced hepatocellular carcinoma (HCC) and main portal vein tumor thrombosis (MPVTT) is unclear." | 9.20 | Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. ( Fan, W; Fu, S; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y, 2015) |
| "To identify clinical biomarkers that could early predict improved survival in patients with advanced-stage hepatocellular carcinoma (HCC) treated with transarterial chemoembolization combined with sorafenib (TACE-S)." | 7.88 | Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. ( Cai, MY; Chen, BH; Guo, YJ; Huang, JJ; Huang, WS; Meng, XC; Zhou, JW; Zhu, KS, 2018) |
| "Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatocellular carcinoma (HCC) of ∼3 months, compared to supportive cares." | 7.83 | Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. ( Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B, 2016) |
| "To compare the therapeutic effect of portal vein stenting and endovascular implantation of iodine-125 seeds strand followed by transcatheter arterial chemoembolization combined with or without sorafenib in patients for hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT)." | 7.83 | [Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus]. ( Chen, LZ; Dai, ZY; Li, CL; Li, WW; Pan, J; Wan, HG; Wang, XJ; Yao, LZ; Zhu, J, 2016) |
| "Patients with advanced hepatocellular carcinoma (aHCC) and portal vein tumor thrombus (PVTT) still have a very poor prognosis, even though the oral multikinase inhibitor sorafenib has revolutionized treatment of aHCC in patients with liver cirrhosis (LC)." | 7.81 | Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. ( Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N, 2015) |
| "Sorafenib (Nexabar, Bayer, Berlin, Germany), one of multikinase inhibitors, can infrequently downstage advanced hepatocellular carcinoma (HCC)." | 7.81 | Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Ishiko, T; Nakamura, K; Nitta, H; Okabe, H; Sasaki, M, 2015) |
| "To explore the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis." | 7.79 | [Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis]. ( Chen, JW; Guo, YJ; Huang, WS; Meng, XC; Pang, PF; Shan, H; Zhou, B; Zhu, KS, 2013) |
| "Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma." | 7.78 | Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012) |
| " Sorafenib combined with transarterial chemoembolization is a novel treatment approach for advanced HCC." | 5.40 | Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. ( Chen, MS; Gao, HJ; Xu, L; Zhang, YJ, 2014) |
| "The survival benefit of combining sorafenib and transarterial chemoembolization (TACE) therapy compared with sorafenib monotherapy for patients with advanced hepatocellular carcinoma (HCC) and main portal vein tumor thrombosis (MPVTT) is unclear." | 5.20 | Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. ( Fan, W; Fu, S; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y, 2015) |
| "To identify clinical biomarkers that could early predict improved survival in patients with advanced-stage hepatocellular carcinoma (HCC) treated with transarterial chemoembolization combined with sorafenib (TACE-S)." | 3.88 | Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. ( Cai, MY; Chen, BH; Guo, YJ; Huang, JJ; Huang, WS; Meng, XC; Zhou, JW; Zhu, KS, 2018) |
| "Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatocellular carcinoma (HCC) of ∼3 months, compared to supportive cares." | 3.83 | Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. ( Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B, 2016) |
| "To compare the therapeutic effect of portal vein stenting and endovascular implantation of iodine-125 seeds strand followed by transcatheter arterial chemoembolization combined with or without sorafenib in patients for hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT)." | 3.83 | [Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus]. ( Chen, LZ; Dai, ZY; Li, CL; Li, WW; Pan, J; Wan, HG; Wang, XJ; Yao, LZ; Zhu, J, 2016) |
| "Patients with advanced hepatocellular carcinoma (aHCC) and portal vein tumor thrombus (PVTT) still have a very poor prognosis, even though the oral multikinase inhibitor sorafenib has revolutionized treatment of aHCC in patients with liver cirrhosis (LC)." | 3.81 | Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. ( Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N, 2015) |
| "Sorafenib (Nexabar, Bayer, Berlin, Germany), one of multikinase inhibitors, can infrequently downstage advanced hepatocellular carcinoma (HCC)." | 3.81 | Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Ishiko, T; Nakamura, K; Nitta, H; Okabe, H; Sasaki, M, 2015) |
| "To explore the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis." | 3.79 | [Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis]. ( Chen, JW; Guo, YJ; Huang, WS; Meng, XC; Pang, PF; Shan, H; Zhou, B; Zhu, KS, 2013) |
| "Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma." | 3.78 | Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012) |
| "Advances in understanding the role of vascular endothelial growth factor (VEGF) in normal physiology are giving insight into the basis of adverse effects attributed to the use of VEGF inhibitors in clinical oncology." | 2.44 | Mechanisms of adverse effects of anti-VEGF therapy for cancer. ( Kamba, T; McDonald, DM, 2007) |
| "The primitive tumor size and the thrombus size were defined by computed tomography before TMT." | 1.40 | Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? ( Ammi, M; Azzouzi, AR; Baumert, H; Beauval, JB; Bensalah, K; Berger, J; Bernhard, JC; Bigot, P; Escudier, B; Fardoun, T; Grenier, N; Hétet, JF; Lagabrielle, S; Lebdai, S; Long, JA; Paparel, P; Patard, JJ; Rioux-Leclercq, N; Rouprêt, M; Soulié, M; Xylinas, E, 2014) |
| " Sorafenib combined with transarterial chemoembolization is a novel treatment approach for advanced HCC." | 1.40 | Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. ( Chen, MS; Gao, HJ; Xu, L; Zhang, YJ, 2014) |
| "In conclusion, AVS inhibited thrombus formation in vivo while it was ineffective in vitro platelet alone system, which may result from the actions of this agent on both platelets and vascular endothelium." | 1.27 | Effects of AVS (1,2-bis(nicotinamido)propane) on platelet function and vascular endothelium. ( Hata, S; Koide, T; Matsushita, H; Mizukami, M; Nakano, M; Neichi, T; Noda, Y; Yamazaki, T, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Zeng, Y | 1 |
| Luo, J | 1 |
| Liao, H | 1 |
| Chen, P | 1 |
| Meng, XC | 2 |
| Chen, BH | 1 |
| Huang, JJ | 1 |
| Huang, WS | 2 |
| Cai, MY | 1 |
| Zhou, JW | 1 |
| Guo, YJ | 2 |
| Zhu, KS | 2 |
| Bigot, P | 1 |
| Fardoun, T | 1 |
| Bernhard, JC | 1 |
| Xylinas, E | 1 |
| Berger, J | 1 |
| Rouprêt, M | 1 |
| Beauval, JB | 1 |
| Lagabrielle, S | 1 |
| Lebdai, S | 1 |
| Ammi, M | 1 |
| Baumert, H | 1 |
| Escudier, B | 1 |
| Grenier, N | 1 |
| Hétet, JF | 1 |
| Long, JA | 1 |
| Paparel, P | 1 |
| Rioux-Leclercq, N | 1 |
| Soulié, M | 1 |
| Azzouzi, AR | 1 |
| Bensalah, K | 1 |
| Patard, JJ | 1 |
| Chen, JW | 1 |
| Pang, PF | 1 |
| Zhou, B | 1 |
| Shan, H | 1 |
| Grieco, A | 1 |
| Lombardo, A | 1 |
| Biolato, M | 1 |
| Gao, HJ | 1 |
| Xu, L | 1 |
| Zhang, YJ | 1 |
| Chen, MS | 1 |
| Garin, E | 1 |
| Rolland, Y | 1 |
| Edeline, J | 1 |
| Icard, N | 1 |
| Lenoir, L | 1 |
| Laffont, S | 1 |
| Mesbah, H | 1 |
| Breton, M | 1 |
| Sulpice, L | 1 |
| Boudjema, K | 1 |
| Rohou, T | 1 |
| Raoul, JL | 1 |
| Clement, B | 1 |
| Boucher, E | 1 |
| Nagai, H | 1 |
| Mukozu, T | 1 |
| Ogino, YU | 1 |
| Matsui, D | 1 |
| Matsui, T | 1 |
| Wakui, N | 1 |
| Momiyama, K | 1 |
| Igarashi, Y | 1 |
| Sumino, Y | 1 |
| Higai, K | 1 |
| Nakamura, K | 1 |
| Beppu, T | 1 |
| Hayashi, H | 1 |
| Okabe, H | 1 |
| Imai, K | 1 |
| Nitta, H | 1 |
| Chikamoto, A | 1 |
| Ishiko, T | 1 |
| Sasaki, M | 1 |
| Baba, H | 1 |
| Zhang, Y | 1 |
| Fan, W | 1 |
| Wang, Y | 1 |
| Lu, L | 1 |
| Fu, S | 1 |
| Yang, J | 1 |
| Huang, Y | 2 |
| Yao, W | 1 |
| Li, J | 1 |
| Matoba, H | 1 |
| Seta, S | 1 |
| Lorenzin, D | 1 |
| Pravisani, R | 1 |
| Leo, CA | 1 |
| Bugiantella, W | 1 |
| Soardo, G | 1 |
| Carnelutti, A | 1 |
| Umberto, B | 1 |
| Risaliti, A | 1 |
| Li, WW | 1 |
| Dai, ZY | 1 |
| Wan, HG | 1 |
| Yao, LZ | 1 |
| Zhu, J | 1 |
| Li, CL | 1 |
| Wang, XJ | 1 |
| Pan, J | 1 |
| Chen, LZ | 1 |
| Colagrande, S | 1 |
| Inghilesi, AL | 1 |
| Aburas, S | 1 |
| Taliani, GG | 1 |
| Nardi, C | 1 |
| Marra, F | 1 |
| Daher, IN | 1 |
| Yeh, ET | 1 |
| Wu, YJ | 1 |
| Zhu, YC | 1 |
| Chen, H | 1 |
| Wei, Q | 1 |
| Chen, HJ | 1 |
| Xie, X | 1 |
| Li, X | 1 |
| Zhou, Q | 1 |
| Yang, YR | 1 |
| Zeng, H | 1 |
| Barbero, C | 1 |
| Salizzoni, S | 1 |
| Centofanti, P | 1 |
| Molino, F | 1 |
| Campisi, P | 1 |
| Giorgi, M | 1 |
| Rinaldi, M | 1 |
| Nishiofuku, H | 1 |
| Tanaka, T | 1 |
| Anai, H | 1 |
| Sueyoshi, S | 1 |
| Maeda, S | 1 |
| Masada, T | 1 |
| Kichikawa, K | 1 |
| Kamba, T | 1 |
| McDonald, DM | 1 |
| Mogielnicki, A | 1 |
| Kramkowski, K | 1 |
| Pietrzak, L | 1 |
| Buczko, W | 1 |
| Mizukami, M | 1 |
| Neichi, T | 1 |
| Yamazaki, T | 1 |
| Koide, T | 1 |
| Noda, Y | 1 |
| Matsushita, H | 1 |
| Hata, S | 1 |
| Nakano, M | 1 |
| Vittori, C | 1 |
| Borri, P | 1 |
| Bianchi, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for niacinamide and Thrombosis
| Article | Year |
|---|---|
Challenges of advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinic | 2016 |
Vascular complications of selected cancer therapies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimet | 2008 |
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
1 trial available for niacinamide and Thrombosis
| Article | Year |
|---|---|
Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hum | 2015 |
18 other studies available for niacinamide and Thrombosis
| Article | Year |
|---|---|
Utility of 18F-Prostate-Specific Membrane Antigen 1007 in Imaging of Tumor Thrombus of Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Fluorine Radioisotopes; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinam | 2021 |
Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2018 |
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Comorbidity; D | 2014 |
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Hepatic | 2013 |
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Heart Diseases; | 2013 |
Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.
Topics: Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Combined Mod | 2014 |
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Topics: Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Europe; False Positive Reactions; Female | 2015 |
Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Ci | 2015 |
Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Loss, Surgical; Carcinoma, Hepatocellular; Combined | 2015 |
[Survival after Sorafenib Treatment for Advanced Recurrent Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; | 2015 |
Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Embolization, Therapeutic; Fema | 2016 |
[Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus].
Topics: Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Endo | 2016 |
Primitive neuroectodermal tumor of the kidney with inferior vena cava tumor thrombus during pregnancy response to sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Kidney Neoplasms; Neuroectodermal T | 2010 |
Right sided heart mass reveals hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Live | 2012 |
Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc | 2012 |
N-methylnicotinamide inhibits arterial thrombosis in hypertensive rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Blood Flow Velocity; Blood Pressure; Carotid Arteries; Collag | 2007 |
Effects of AVS (1,2-bis(nicotinamido)propane) on platelet function and vascular endothelium.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Blood Vessels; Cerebrovascul | 1984 |
[On the comparative results of the use of Clarisco in peripheral vascular diseases].
Topics: Aged; Arteriosclerosis Obliterans; Choline; Coronary Disease; Folic Acid; Gangrene; Heparin; Humans; | 1970 |